An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- AIDS
- HIV Infections
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Infusion of autologous CD34+ cells transduced with shRNAs targeting CCR5 and HIV genomeMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 50 years
- Gender
- Both males and females
Description
CD34+ cells will be isolated from mobilized PBMC of HIV patients. The cells will be lentivirally transduced with multiplexed shRNAs in the same vector that target CCR5 and HIV genome. Such modified cells will be infused back to the patients who have received bulsufan preconditioning before infusion....
CD34+ cells will be isolated from mobilized PBMC of HIV patients. The cells will be lentivirally transduced with multiplexed shRNAs in the same vector that target CCR5 and HIV genome. Such modified cells will be infused back to the patients who have received bulsufan preconditioning before infusion. The patients will then be evaluated for efficacy and safety.
Tracking Information
- NCT #
- NCT03517631
- Collaborators
- R&D Kanglin Biotech
- Investigators
- Study Director: Hongzhou Lu, Ph.D Caolang Road NO. 2901, Jinshan District, Shanghai
Get Well Soon